Valuation : Glenmark Pharmaceuticals Limited

Market Cap 70TCr 734.57Cr 633.64Cr 596.03Cr 543Cr 1.02TCr 1.03TCr 7.05TCr 2.74TCr 35TCr 2.76TCr 2.7TCr 1,17600Cr P/E 2027 *
30x
P/E 2028 * 25x
Enterprise Value 66TCr 696.12Cr 600.47Cr 564.84Cr 514.58Cr 967.65Cr 972.89Cr 6.68TCr 2.6TCr 34TCr 2.61TCr 2.56TCr 1,11400Cr EV / Sales 2027 *
3.93x
EV / Sales 2028 * 3.47x
Free-Float
51.04%
Yield 2027 *
0.15%
Yield 2028 * 0.16%
1 day-1.40%
1 week-0.10%
Current month-1.78%
1 month+9.23%
3 months+11.50%
6 months+14.72%
Current year+19.69%
1 week 2,420
Extreme 2420
2,537.6
1 month 2,162
Extreme 2162
2,537.6
Current year 1,842
Extreme 1842
2,537.6
1 year 1,792.6
Extreme 1792.6
2,537.6
3 years 722.1
Extreme 722.1
2,537.6
5 years 348.5
Extreme 348.5
2,537.6
10 years 161.65
Extreme 161.65
2,537.6
Manager TitleAgeSince
Chief Executive Officer 56 01/01/2000
Director of Finance/CFO 54 27/05/2025
President - 15/09/2023
Director TitleAgeSince
Director/Board Member 58 -
Chairman 56 12/05/2011
Director/Board Member 86 14/08/2009
Change 5-day change 1-year change 3-year change Capi.($)
-1.40%-0.10%+26.95%+219.88% 734.57Cr
-0.15%+1.40%+23.05%+73.69% 4.88TCr
-1.61%-0.29%+51.58%+118.38% 4.07TCr
-1.04%+0.50%+16.02%+86.25% 1.23TCr
-0.82%+0.64%-10.04%+13.95% 1.21TCr
+0.57%+1.73%+31.59%+153.11% 928.38Cr
-0.99%-2.33%+25.02%+45.46% 755.42Cr
-0.62%-0.84%+44.70%-11.26% 729.62Cr
-0.13%-0.16%-40.47%+15.85% 525.5Cr
-2.07%-3.37%+38.40%+99.60% 461.38Cr
Average -0.82%+0.79%+20.68%+81.49% 1.55TCr
Weighted average by Cap. -0.79%+1.17%+27.50%+86.85%

Financials

2027 *2028 *
Net sales 17TCr 176.94Cr 152.63Cr 143.57Cr 130.79Cr 245.96Cr 247.29Cr 1.7TCr 660.62Cr 8.54TCr 664.31Cr 649.91Cr 28TCr 19TCr 197.17Cr 170.08Cr 159.98Cr 145.75Cr 274.07Cr 275.56Cr 1.89TCr 736.14Cr 9.52TCr 740.26Cr 724.21Cr 32TCr
Net income 2.31TCr 24Cr 21Cr 20Cr 18Cr 34Cr 34Cr 233.58Cr 91Cr 1.18TCr 91Cr 89Cr 3.9TCr 2.77TCr 29Cr 25Cr 24Cr 22Cr 41Cr 41Cr 280.04Cr 109Cr 1.41TCr 109.61Cr 107.23Cr 4.67TCr
Net Debt -3.65TCr -38Cr -33Cr -31Cr -28Cr -53Cr -54Cr -368.82Cr -143.55Cr -1.86TCr -144.36Cr -141.23Cr -6.15TCr -4.8TCr -51Cr -44Cr -41Cr -37Cr -70Cr -71Cr -485.18Cr -188.84Cr -2.44TCr -189.9Cr -185.78Cr -8.1TCr
Logo Glenmark Pharmaceuticals Limited
Glenmark Pharmaceuticals Limited is an India-based, research-led, global pharmaceutical company. The Company hosts a diverse portfolio spanning branded, generics, and over-the-counter (OTC) segments. The Company is focused on the therapy areas of Respiratory, Dermatology and Oncology. The Company also has a regional/country-specific presence in other therapeutic areas like diabetes, cardiovascular and oral contraceptives. The Company’s offerings include complex injectables and biologics, oral solids, liquids, topical products, respiratory mdi1/dpi2/nasal sprays. It is focused on developing products for markets such as India, Russia & CIS, Brazil, Asia and Africa. Its brands include RYALTRIS and SALMEX / ASTHMEX. RYALTRIS, the Company's first global branded specialty drug for treating symptoms of seasonal allergic rhinitis. The Company's subsidiaries include Glenmark Pharmaceuticals Inc., Ichnos Sciences Inc., and Glenmark Holding SA.
Employees
16,946
Date Price Change Volume
02/26/02 2,435.90 -1.40% 3,42,066
01/26/01 ₹2,470.40 -0.39% 6,79,565
31/26/31 ₹2,480.00 -1.39% 9,11,026
28/26/28 ₹2,515.00 +2.24% 8,07,816
27/26/27 ₹2,460.00 +0.89% 4,47,011
Trader
Investor
Global
Quality
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
2,470.40INR
Average target price
2,497.73INR
Spread / Average Target
+1.11%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. GLENMARK Stock